News

February 14, 2019

Xtandi Delays Disease Progression, Death in Metastatic Hormone-Sensitive PC Patients, Trial Shows

News

Adding the androgen receptor inhibitor Xtandi (enzalutamide) to androgen deprivation therapy (ADT) significantly delays disease progression — assessed through radiological imaging — or death among metastatic hormone-sensitive prostate cancer patients, ... Read more

February 13, 2019

Grants Will Fuel UK Researchers’ Drive Toward Prostate Cancer-Killing Virus

News

Scientists from the Queen Mary University of London have received grants worth more than £2.5 million ($3.2 million), awarded by Prostate Cancer UK to advance prostate cancer research. The funds, which ... Read more

February 11, 2019

University of Minnesota Team Receives $1M to Develop CAR-NK Therapy

News

The Prostate Cancer Foundation (PCF) has granted a $1 million Challenge Award to researchers from the Masonic Cancer Center at the University of Minnesota to support their investigations into new ... Read more

February 7, 2019

HPN424 Shows Promising Safety, Immune Activation in Metastatic CRPC

News

Preliminary data from an ongoing Phase 1 trial suggest that Harpoon Therapeutics’ investigational therapy HPN424 is safe and effectively activates the immune system in metastatic castration resistant prostate cancer (mCRPC) ... Read more

February 6, 2019

Precision Radiation Therapy to Treat Prostate Cancer Spread Safe for High-Risk Patients, Phase 2 Trial Finds

News

Prostate cancer patients at a high risk of tumor spreading can safely receive high-dose radiation therapy that targets both the prostate and neighboring pelvic lymph nodes, a Phase 2 ... Read more

February 4, 2019

Erleada Improves Survival in Metastatic Castration-Sensitive Prostate Cancer, Phase 3 Trial Finds

News

Adding Janssen‘s androgen receptor inhibitor Erleada (apalutamide) to first-line androgen deprivation therapy (ADT) significantly extended survival and delayed disease progression or death in metastatic castration-sensitive prostate cancer patients included in a Phase ... Read more

January 31, 2019

Using Finasteride as Preventive Does Not Raise Chances of Dying from Prostate Cancer, Analysis Contends

News

Using finasteride to prevent prostate cancer does not raise the chances of dying from the disease among men who develop it, a recent analysis of the Prostate Cancer Prevention Trial (PCPT) shows. The study addresses ... Read more

January 30, 2019January 30, 2019

FDA Clears Phase 1 Trial of ARV-110 for Advanced Prostate Cancer

News

The U.S. Food and Drug Administration has signed off on Arvinas‘ first Phase 1 clinical trial to evaluate ARV-110 as a therapy for patients with metastatic castration-resistant prostate cancer (mCRPC). ... Read more

January 24, 2019

Researchers Develop Computer Model to Predict Prostate Cancer Progression

News

A new study has yielded a new computer model to understand the progression of prostate cancer, which may yield insights into understanding the disease and providing care for patients. ... Read more

January 23, 2019

New Advisory Council Member to Push Continued Support of Movember Foundation Mission

News

The recent appointment of DMC Atlanta president Adam Dorfman to the Australian-based Movember Foundation National Advisory Council reflects the direct marketing and sales firm’s continuing advocacy of the foundation’s ... Read more

Pin It on Pinterest